Stock code: 4116

BENQ MEDICAL TECHNOLOGY CORP. AND SUBSIDIARIES

Consolidated Financial Statements and Independent Auditors' Review Report

For the Three Months Ended March 31, 2026 and 2025

Company Address: 7F, No. 46, Zhouzi St., Neihu Dist., Taipei 11493, Taiwan
Telephone: (02) 8797-5533

The independent auditors' review report and the accompanying financial statements are the English translation of Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

Table of Contents

Independent Auditors' Review Report

The Board of Directors
BENQ MEDICAL TECHNOLOGY CORP.

Foreword

We have reviewed the Consolidated Balance Sheets as of March 31, 2026 and 2025, and Consolidated Statements of Comprehensive Income, Consolidated Statements of Changes in Equity, and Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025, as well as Notes to consolidated financial statements (including summary of significant accounting policies) of BENQ MEDICAL TECHNOLOGY CORP. AND SUBSIDIARIES. The Management is responsible for preparing the consolidated financial statements with fair representation in accordance with "Regulations Governing the Preparation of Financial Reports by Securities Issuers" and International Accounting Standards 34, "Interim Financial Reporting" as endorsed by Financial Supervisory Commission of the Republic of China of the Republic of China. Our responsibility is to express a conclusion based on our review of the consolidated financial statements.

Scope of Review

Except as explained in the Basis for Qualified Conclusion paragraph, we conducted our review in accordance with the Statement on Review Engagements of the Republic of China 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". The process of reviewing the consolidated financial statements includes making enquiries (mainly to personnel in charge of financial and accounting matters), analyzing, and other reviewing procedures. The scope of review is substantially less than the scope of an audit. As such, we may not be able to obtain assurance on all significant matters that an audit could otherwise provide, and therefore we are unable to express an audit opinion.

Basis for Qualified Conclusions

As stated in Note 4(2), the consolidated financial statements included in the financial statements of certain non-significant subsidiaries, which were not reviewed by independent auditors. These financial statements reflect the total assets amounting to NTD750,062 thousand and NTD966,479 thousand, constituting 13% and 18% of the consolidated total assets as of March 31, 2026 and 2025, respectively; and the total liabilities amounting to NTD186,972 thousand and NTD310,455 thousand, constituting 6% and 10% of the consolidated total liabilities of as of March 31, 2026 and 2025, respectively; as well as total comprehensive income (loss) for the three months ended March 31, 2026 and 2025 amounting to NTD14,290 thousand and NTD(478) thousand, constituting 27% and (1)% , respectively.

Qualified Conclusion

Except for the adjustment, if any, as might have been determined to be necessary had the financial statements of certain consolidated subsidiaries and equity accounted invest companies described in the Basis of Qualified Conclusion paragraph above been reviewed by independent auditors, based on the results of our review, nothing has come to our attention that the consolidated financial statements are in any incompliance of "Regulations Governing the Preparation of Financial Reports by Securities Issuers" and International Accounting Standards 34, "Interim Financial Reporting" as endorsed by Financial Supervisory Commission of the Republic of China of the Republic of China, such that the consolidated financial position of BENQ MEDICAL TECHNOLOGY CORP. AND SUBSIDIARIES as of March 31, 2026 and 2025, and the consolidated financial performance and the consolidated cash flows for the three months ended March 31, 2026 and 2025 do not present fairly.

The engagement partners on the review resulting in this independent auditors' review report are Hsu, Shih-Chun and Shih, Wei-Ming.

KPMG
Taipei, Taiwan (Republic of China)
May 04, 2026

<u>Notes to Readers</u>

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' review report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' review report and consolidated financial statements, the Chinese version shall prevail.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BENQ MEDICAL TECHNOLOGY CORPORATION AND SUBSIDIARIES

Consolidated Balance Sheets

March 31, 2026, and December 31 and March 31, 2025

(Expressed in Thousands of New Taiwan Dollars)

		2026.03.31		2025.12.31		2025.03.31	
	Assets	**Amount**	**%**	**Amount**	**%**	**Amount**	**%**
	Current assets:						
1100	Cash and cash equivalents (Note 6(1))	$ 886,916	16	949,326	18	854,659	16
1136	Financial assets measured at amortized cost - current (Note 6(2) and 8)	244,451	4	286,382	5	249,983	5
1150-1170	Notes and accounts receivable (Note 6(5) and (23))	1,003,578	18	952,020	18	877,574	17
1181	Accounts receivable - related parties (Note 6(5)(23) and 7)	5,168	-	16,527	-	5,718	-
1200	Other receivables	14,164	-	9,264	-	8,834	-
130x	Inventories (Note 6(6))	906,623	16	892,879	16	905,562	17
1410-1470	Prepayments and other current assets	161,526	3	163,666	3	182,399	3
1461	Non-current assets held for sale (Note 6(7) and 8)	422,541	8	422,541	8	57,882	1
	Total current assets	3,644,967	65	3,692,605	68	3,142,611	59
	Non-current assets:						
1510	Financial assets at fair value through profit or loss - non-current (Note 6(3))	55,785	1	53,796	1	-	-
1518	Financial assets at fair value through other comprehensive income - non-current (Note 6(4))	123	-	123	-	20,197	-
1535	Financial assets measured at amortized cost – non-current (Note 6(2) and 8)	61,111	1	61,137	1	-	-
1600	Property, plant and equipment (Note 6(9), 7, and 8)	532,585	9	548,075	10	918,434	17
1755	Right-of-use assets (Note 6(10) and 7)	175,026	3	175,558	3	209,902	4
1760	Investment properties - net (Note 6(11) and 8)	364,819	7	371,827	7	462,490	9
1780	Intangible assets (Note 6(12) and 7)	424,548	8	427,090	8	423,018	8
1840	Deferred income tax assets	32,385	1	32,416	-	28,287	1
1900	Other non-current assets (Note 6(13))	293,453	5	87,984	2	92,889	2
	Total non-current assets	1,939,835	35	1,758,006	32	2,155,217	41
	Total assets	$ 5,584,802	100	5,450,611	100	5,297,828	100

		2026.03.31		2025.12.31		2025.03.31	
	Liabilities and Equity	**Amount**	**%**	**Amount**	**%**	**Amount**	**%**
	Current liabilities:						
2100	Short-term loans (Note 6(14) and 8)	$ 809,766	14	868,675	16	680,719	13
2110	Short-term notes payable (Note 6(14) and 8)	25,984	-	25,852	-	-	-
2131	Contract liabilities-current (Note 6(23))	37,560	1	35,306	1	32,710	1
2150-2170	Notes and accounts payable	563,159	10	571,469	11	524,684	10
2181	Accounts payable - related parties (Note 7)	34,085	1	35,501	1	37,194	1
2200	Other payable (Note 6 (8)(12) and (24))	393,760	7	329,555	6	331,153	6
2220	Other payable - related parties (Note 7)	4,238	-	4,521	-	6,860	-
2230	Current income tax liabilities	58,195	1	44,584	1	56,761	1
2250	Provisions for liabilities - current (Note 6(17))	4,116	-	3,872	-	2,750	-
2280	Lease liabilities - current (Note 6(16) and 7)	96,574	2	102,519	2	102,512	2
2300	Other current liabilities	10,749	-	16,672	-	13,107	-
2322	Long-term loans due within a year (Note 6(15) and 8)	250,000	5	238,750	4	80,078	1
	Total current liabilities	2,288,186	41	2,277,276	42	1,868,528	35
	Non-current liabilities:						
2540	Long-term loans (Note 6(15) and 8)	758,449	14	534,370	10	825,059	16
2570	Deferred income tax liabilities	48,988	1	46,638	1	44,115	1
2580	Lease liabilities - non-current (Note 6(16) and 7)	214,506	4	218,633	4	268,938	5
2645	Guarantee deposit received	11,595	-	12,848	-	6,768	-
2670	Other non-current liabilities (Note 6(12))	20,502	-	30,093	-	29,066	-
	Total non-current liabilities	1,054,040	19	842,582	15	1,173,946	22
	Total liabilities	3,342,226	60	3,119,858	57	3,042,474	57
	Equity attributable to shareholders of the parent company (Note 6(21)):						
3110	Common stock	445,660	8	445,660	8	445,660	8
3200	Capital Surplus	298,107	6	298,107	6	297,921	6
3300	Retained earnings	305,127	5	386,453	7	329,332	6
3400	Other equity	(1,528)	-	(3,545)	-	301	-
	Total equity attributable to shareholders of the parent company	1,047,366	19	1,126,675	21	1,073,214	20
36XX	**Non-controlling interests (Note 6(8) and (21))**	1,195,210	21	1,204,078	22	1,182,140	23
	Total equity	2,242,576	40	2,330,753	43	2,255,354	43
	Total liabilities and equity	$ 5,584,802	100	5,450,611	100	5,297,828	100

(Please see Notes to Consolidated Financial Statements)

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BENQ MEDICAL TECHNOLOGY CORPORATION AND SUBSIDIARIES

Consolidated Statements of Comprehensive Income

For the three months ended March 31, 2026 and 2025

(Expressed in Thousands of New Taiwan Dollars)

Code	Item	January to March 2026 Amount	%	January to March 2025 Amount	%
4000	**Operating revenues (Note 6 (18)(23), 7 and 14)**	$ 1,324,607	100	1,227,958	100
5000	**Costs of revenue (Note 6 (6)(9)(10)(11)(12)(16)(17)(18)(19)(24), 7 and 12)**	(897,434)	(68)	(831,758)	(68)
	Gross profit	427,173	32	396,200	32
	Operating expenses (Note 6 (5)(9)(10)(11)(12)(16)(18)(19)(24), 7 and 12):				
6100	Selling expenses	(283,910)	(21)	(256,815)	(21)
6200	General and administrative expenses	(64,173)	(5)	(57,584)	(5)
6300	Research and development expenses	(8,654)	(1)	(8,257)	-
6450	Impairment loss for expected credit losses	(964)	-	(694)	-
	Total operating expenses	(357,701)	(27)	(323,350)	(26)
	Operating income	69,472	5	72,850	6
	Non-operating income and loss (Note 6 (16)(18)(25) and 7):				
7100	Interest income	2,287	-	1,718	-
7010	Other income	8,135	1	3,941	1
7020	Other gains and losses	4,672	1	2,102	-
7050	Financing costs	(11,675)	(1)	(10,683)	(1)
	Total non-operating income and loss	3,419	1	(2,922)	-
	Income before income tax	72,891	6	69,928	6
7950	**less: Income tax expenses (Note 6(20))**	(22,990)	(2)	(20,096)	(2)
	Net income	49,901	4	49,832	4
	Other comprehensive income (loss) (Note 6(21)):				
8360	**Items that will not be reclassified to profit or loss**				
8361	Unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	-	-	74	-
8399	Income tax related to items that may not be reclassified subsequently to profit or loss	-	-	-	-
	Total items that may not be reclassified subsequently to profit or loss	-	-	74	-
8360	**Items that may be reclassified subsequently to profit or loss**				
8361	Exchange differences on translation of foreign operations	2,674	-	5,598	1
8399	Income tax related to items that may be reclassified subsequently to profit or loss	-	-	-	-
	Total items that may be reclassified subsequently to profit or loss	2,674	-	5,598	1
	Other comprehensive income (loss) for the period	2,674	-	5,672	1
	Total comprehensive income (loss) for the period	$ 52,575	4	55,504	5
	Net Income attributable to:				
8610	Owners of the parent	$ 12,566	1	22,278	2
8620	Non-controlling interest	37,335	3	27,554	2
		$ 49,901	4	49,832	4
	Comprehensive income (loss) attributable to:				
8710	Owners of the parent	$ 14,583	1	24,689	2
8720	Non-controlling interest	37,992	3	30,815	3
		$ 52,575	4	55,504	5
	Earnings per share (in New Taiwan dollars, Note 6 (22))				
9750	**Basic earnings per share**	$	0.28		0.50
9850	**Diluted earnings per share**	$	0.28		0.50

(Please see Notes to Consolidated Financial Statements)

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BENQ MEDICAL TECHNOLOGY CORPORATION AND SUBSIDIARIES

Consolidated Statements of Changes in Equity

For the three months ended March 31, 2026 and 2025

(Expressed in Thousands of New Taiwan Dollars)

	Equity attributable to shareholders of the parent company										
			Retained earnings				Other equity				
	Common stock	Capital surplus	Legal reserve	Special reserve	Unappropriated earnings	Subtotal	Foreign currency translation differences	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	Total equity attributable to shareholders of the parent company	Non-controlling interests	Total equity
Balance as of January 01, 2025	$ 445,660	297,921	123,417	5,560	251,611	380,588	(2,110)	-	1,122,059	1,178,194	2,300,253
Net income	-	-	-	-	22,278	22,278	-	-	22,278	27,554	49,832
Other comprehensive income for the period	-	-	-	-	-	-	2,382	29	2,411	3,261	5,672
Total comprehensive income for the period	-	-	-	-	22,278	22,278	2,382	29	24,689	30,815	55,504
Earnings appropriation and distribution:											
Cash dividends of ordinary shares	-	-	-	-	(73,534)	(73,534)	-	-	(73,534)	-	(73,534)
Cash dividends distributed to non-controlling interests by subsidiaries	-	-	-	-	-	-	-	-	-	(26,869)	(26,869)
Balance as of March 31, 2025	**$ 445,660**	**297,921**		**5,560**	**200,355**	**329,332**	**272**	**29**	**1,073,214**	**1,182,140**	**2,255,354**
Balance as of January 01, 2026	$ 445,660	298,107	134,208	2,110	250,135	386,453	(3,545)	-	1,126,675	1,204,078	2,330,753
Net income	-	-	-	-	12,566	12,566	-	-	12,566	37,335	49,901
Other comprehensive income for the period	-	-	-	-	-	-	2,017	-	2,017	657	2,674
Total comprehensive income for the period	-	-	-	-	12,566	12,566	2,017	-	14,583	37,992	52,575
Earnings appropriation and distribution:											
Cash dividends of ordinary shares	-	-	-	-	(89,132)	(89,132)	-	-	(89,132)	-	(89,132)
Cash dividends distributed to non-controlling interests by subsidiaries	-	-	-	-	-	-	-	-	-	(39,620)	(39,620)
Changes in ownership interests in subsidiaries	-	-	-	-	(4,760)	(4,760)	-	-	(4,760)	(7,240)	(12,000)
Balance as of March 31, 2026	**$ 445,660**	**298,107**		**2,110**	**168,809**	**305,127**	**(1,528)**	**-**	**1,047,366**	**1,195,210**	**2,242,576**

(Please see Notes to Consolidated Financial Statements)

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BENQ MEDICAL TECHNOLOGY CORPORATION AND SUBSIDIARIES

Consolidated Statements of Cash Flows

For the three months ended March 31, 2026 and 2025

(Expressed in Thousands of New Taiwan Dollars)

	January to March 2026	January to March 2025
Cash flows from operating activities:		
Profit before income tax	$ 72,891	69,928
Adjustments:		
Adjustments to reconcile profit (loss)		
Depreciation	58,945	61,430
Amortization	6,971	6,269
Impairment loss for expected credit losses	964	692
Net gain on financial instruments at fair value through profit or loss	(1,989)	-
Interest expense	11,675	10,683
Interest income	(2,287)	(1,718)
Dividend income	(4,864)	-
Gain on disposals of property, plant and equipment	(74)	(384)
Gains on lease modification	(30)	(11)
Total adjustments to reconcile profit (loss)	69,311	76,961
Changes in operating assets and liabilities:		
Changes in operating assets:		
Notes and accounts receivable	(51,062)	21,125
Accounts receivable - related parties	11,359	367
Other receivables	(6,890)	258
Inventories	(17,970)	(122,437)
Prepayments and other current assets	2,140	23,688
Total changes in operating assets	(62,423)	(76,999)
Changes in operating liabilities:		
Contract liabilities	2,254	3,232
Notes and accounts payable	(8,310)	(66,357)
Accounts payable - related parties	(1,416)	3,834
Other payables	(25,029)	(38,875)
Other payables - related parties	(283)	1,944
Provisions for liabilities	244	(330)
Other current liabilities	(5,923)	(3,071)
Net defined benefit liabilities	16	13
Total changes in operating liabilities	(38,447)	(99,610)
Total changes in operating assets and liabilities	(100,870)	(176,609)
Total adjustments	(31,559)	(99,648)
Cash provided by (used in) operations	41,332	(29,720)
Interest received	1,805	1,742
Dividend received	4,864	-
Interest paid	(11,048)	(10,706)
Income tax paid	(6,998)	(7,286)
Net cash flow provided by (used in) operating activities	29,955	(45,970)

(Please see Notes to Consolidated Financial Statements)

(Continued on next page)

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BENQ MEDICAL TECHNOLOGY CORPORATION AND SUBSIDIARIES

Consolidated Statements of Cash Flows (continued from the preceding page)

For the three months ended March 31, 2026 and 2025

(Expressed in Thousands of New Taiwan Dollars)

	January to March 2026	January to March 2025
Cash flows from investing activities:		
Increase in prepayment for investments	(200,000)	-
Acquisition of subsidiaries	-	(21,262)
Net cash flows used in acquisition of business transfer	(10,000)	(5,000)
Acquisition of property, plant and equipment	(11,540)	(41,256)
Proceeds from disposal of property, plant and equipment	1,972	2,942
Increase in refundable deposits	(3,310)	-
Decrease in refundable deposits	-	1,793
Acquisition of intangible assets	(4,432)	(357)
Increase in other non-current assets	(2,351)	(3,389)
Decrease in Financial assets measured at amortized cost	41,931	79,000
Net cash flow provided by (used in) investing activities	(187,730)	12,471
Cash flows from financing activities:		
Increase in short-term loans	(58,909)	100,016
Increase in long-term loans	260,000	150,000
Repayments of long-term loans	(24,671)	(198,639)
Decrease in guarantee deposit received	(1,253)	(123)
Payment of lease liabilities	(31,765)	(25,493)
Cash dividends distributed to non-controlling interests by subsidiaries	(39,620)	(4,869)
Acquisition of non-controlling interest (NCI) in a subsidiary	(12,000)	-
Net cash flow provided by (used in) financing activities	91,782	20,892
Effect of changes in foreign exchange rates	3,583	4,075
Decrease in cash and cash equivalents for the current period	(62,410)	(8,532)
Cash and cash equivalents at the beginning of the period	949,326	863,191
Cash and cash equivalents at the end of the period	$ 886,916	854,659

(Please see Notes to Consolidated Financial Statements)

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

BENQ MEDICAL TECHNOLOGY CORPORATION AND SUBSIDIARIES

Notes to Consolidated Financial Statements

For the three months ended March 31, 2026 and 2025

(Unless stated otherwise, all amounts are expressed in thousands of New Taiwan Dollar)

1. History and Organization

BENQ MEDICAL TECHNOLOGY CORP. (hereafter the Company), formerly known as Trident Medical Corp., received authorization from the Ministry of Economic Affairs for its incorporation on March 21, 1989, at 7F, No. 46, Zhouzi St., Neihu Dist., Taipei 11493, Taiwan. The main business operation of the Company and Subsidiaries (hereafter the Group) includes the manufacturing, installation, maintenance, repair of medical devices and various types of medical equipment, and the wholesales and retailing of medical devices and equipment, medication and health supplements, as well as the provision of leasing, management and consultation services of medical devices.

2. Authorization of the Consolidated Financial Statements

These Consolidated Financial Statements were approved by the Board of Directors on May 04, 2026 before being issued.

3. Application of New Standards, Amendments, and Interpretations

(1) Effects of the adoption of new standards, amendments, and interpretations as endorsed by the Financial Supervisory Commission (FSC) of the Republic of China

The Group began to apply the following amendments to International Financial Reporting Standards and International Accounting Standards from January 01, 2026 onward, and there has been no significant impact on the Group's Consolidated Financial Statements.

- IFRS 17 "Insurance Contracts" and Amendments to IFRS 17
- Amendments to IFRS 9 and IFRS 7 "Amendments to the Classification and Measurement of Financial Instruments"
- Annual improvements to IFRS Accounting Standards
- Amendments to IFRS 9 and IFRS 7 "Contracts Referencing Nature-dependent Electricity"

(3) New standards, amendments and interpretations that have yet endorsed by FSC

IFRS, IAS, IFRIC and SIC that have been issued by the International Accounting Standards Board (IASB) but have yet to be endorsed and issued into effect by the FSC, and which may be relevant to the Group.

Newly issued or amended standards and interpretation	Main content of the amendments	Effective date by International Accounting Standard Board
IFRS 18, "Presentation and Disclosure in Financial Statements"	The new standard introduces three categories of income and expenses, two income statement subtotals and one single note on management performance measures. The three amendments, combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities. • A more structured income statement: Under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined 'operating profit' subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company's main business activities. • Management performance measures (MPMs): The new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards. • Greater disaggregation of information: The new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes.	January 01, 2027 Note: On September 25, 2025, FSC announced that IFRS 18 will take effect starting from January 1, 2028. Listed entities could choose to apply IFRS 18 for an earlier period after the endorsement of IFRS 18 by FSC.

The Group is evaluating the impact of the above IFRSs and Interpretation on the Consolidated Financial Statements and business operations. The relevant impact shall be disclosed once the evaluation is concluded.

The Group expects the following new standards, amendments and interpretations that have yet to be endorsed by FSC shall not pose a significant impact on the Consolidated

Financial Statements.

- Amendments to IFRS 10 and IAS 28, "Sale or Contribution of Assets between an Investor and its Associate or Joint Venture"
- IFRS 19 "Subsidiaries without Public Accountability" and Amendments to IFRS 19
- Amendments to IFRS 21, "Translation to a Hyperinflationary Presentation Currency"

4. Summary of Significant Accounting Policies

(1) Statement of compliance

These Consolidated Financial Statements are prepared in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" (hereafter "the Preparation Regulations") and the IAS 34, "Interim Financial Reporting" as endorsed by FSC. These Consolidated Financial Statements do not include all necessary disclosure as in the yearly consolidated financial statements prepared in accordance with IFRSs, IASs, Interpretations and SIC Interpretations as endorsed by FSC (hereafter "Taiwan-IFRSs and IASs").

Except for the following, the significant accounting policies of these Consolidated Financial Statements are identical to the Consolidated Financial Statements for 2025. For more information, please see Note 4 to Consolidated Financial Statements for 2025.

(2) Basis of consolidation

The basis of consolidation of these Consolidated Financial Statements are identical to the Consolidated Financial Statements for 2025. For more information, please see Note 4(3) to Consolidated Financial Statements for 2025.

1. Subsidiaries included in the Consolidated Financial Statements

Subsidiaries included in these Consolidated Financial Statements:

Investor	Subsidiary	Main business activities	Ownership (%) 2026.03.31	2025.12.31	2025.03.31	Description
The Company	AsiaConnect International Co., Ltd. (ACI)	Sales of medical consumables and equipment and wholesaling and retailing of information software	99.75%	99.75%	99.75%	(Note 10) (Note 11)
The Company	Highview Investments Limited (Highview)	Investment and holding company	-	-	100.00%	(Note 2) (Note 10)
The Company	LILY Medical Corporation (LILY)	Wholesaling and retailing of medical consumables and equipment	100.00%	100.00%	100.00%	
The Company	BenQ AB DentCare Corporation (BABD)	Wholesaling and retailing of medical consumables and equipment	100.00%	88.00%	88.00%	(Note 3) (Note 10) (Note 11)
The Company	BenQ Healthcare Corporation (BHS)	Wholesaling and retailing of medical consumables and equipment	100.00%	100.00%	100.00%	
The Company	Eastech Co., Ltd (ETC)	Wholesaling and retailing of medical consumables and equipment	70.00%	70.00%	70.00%	(Note 10) (Note 11)
The Company	Concord Medical Co., Ltd. (CCD)	Sale of medical drugs, leasing of medical equipment and provision of management consultation services	40.00%	40.00%	40.00%	(Note 1)
The Company	BenQ Medical Technology (Shanghai) Ltd. (BMTS)	Agency of international and entrepot trade business	100.00%	100.00%	100.00%	(Note 9) (Note 10) (Note 11)

Investor	Subsidiary	Main business activities	Ownership (%) 2026.03.31	2025.12.31	2025.03.31	Description
CCD	Concord HealthCare Co., Ltd. (CCHC)	Wholesaling and retailing of medical consumables and equipment and provision of management consulting services	40.00%	40.00%	40.00%	(Note 10) (Note 11)
CCD	Concord BioMedical Co., Ltd. (CBM)	Wholesale and retail of animal pharmaceuticals and medical devices	21.62%	21.62%	-	(Note 4) (Note 11)
CCD	Concord BioTech Co., Ltd. (CBT)	Medical testing and consulting services	20.33%	20.33%	-	(Note 8) (Note 11)
BMTS	BenQ Smart Healthcare (Shanghai) Co.,Ltd. (BSHS)	Wholesaling and retailing of medical consumables and equipment	100.00%	100.00%	100.00%	(Note 10) (Note 11)
BHS	New Best Hearing International Trade Co., Ltd. (NBHIT)	Wholesaling and retailing of medical consumables and equipment	52.00%	52.00%	52.00%	
BHS	CKCARE Co., Ltd. (CKCARE)	Retail of medical devices, over-the-counter drugs, and health supplements	60.00%	60.00%	60.00%	(Note 10)
The Company and ACI	K2 International Medical Inc. (K2)	Sale of medical consumables and equipment	40.00%	40.00%	40.00%	
K2	K2 Medical (Thailand) Co., Ltd. (K2 Thailand)	Sale of medical consumables and equipment	31.86%	31.86%	19.60%	(Note 7)
K2	K2 (Shanghai) International Medical Inc.	Sale of medical consumables and equipment	40.00%	40.00%	40.00%	(Note 6) (Note 11)
K2	PT. Frismed Hoslab Indonesia (K2 Indonesia)	Blood banking equipment and supplies	26.80%	26.80%	26.80%	(Note 6)
K2	Era Bioteq Enterprise Co., Ltd. (ERA)	Sales of endoscopic consumables and equipment	24.00%	24.00%	-	(Note 6) (Note 10)
K2 Thailand	K2 BioMedical Co., Ltd.	Sale of medical consumables and equipment	39.61%	39.61%	-	(Note 5) (Note 6) (Note 11)

(Note 1): The Group has a shareholding of 40% of CCD and represents the single largest shareholder. The remaining 60% shareholding of CCD does not concentrate on any specific shareholder, and as per the participation level of shareholders in the previous general shareholder's meeting, the Group proved to possess more than half of the total voting rights amongst the shareholders attending the meeting. Thus, the Group deems itself to have control over CCD.

(Note 2): Highview completed liquidation in 2025.

(Note 3): The Group originally held 88% shareholding in BABD. On March 05, 2026, the Group acquired 12% shareholding from non-controlling interests, bringing its total ownership to 100%. The legal registration of this acquisition was completed on March 24, 2026.

(Note 4): The consolidated subsidiary CCD acquired a 54.05% equity interest in CBM on April 01, 2025.

(Note 5): The consolidated subsidiary K2 Medical (Thailand) Co., Ltd. acquired a 99% equity interest in K2 BioMedical Co., Ltd. on August 01, 2025.

(Note 6): Although holding less than half of comprehensive shareholding in the company, the Group has more than half of direct and indirect voting shares of the company; therefore, it is determined that the Group has control over the company.

(Note 7): Although the Group does not hold more than half of the voting rights of the company, the Group signed a contract with other shareholders to entrust the authorization of voting rights to the company to exercise the voting rights. After assessment, the Group has control over such company. On May 01, 2025, after the Group additionally acquired 45% of the ordinary shares of the Company from non-controlling interests, it held a total of 94% of the voting shares of the company and obtained control over the Company.

(Note 8): The consolidated subsidiary CCD acquired a 50.82% equity interest in CBT on October 01, 2025.

(Note 9): Highview originally held 100% of the equity in BMTS and sold it to the Company in May 2025.

(Note 10): Insignificant subsidiary and its financial statement for the three months ended March 31, 2025 has not been reviewed by an independent auditor.

(Note 11): Insignificant subsidiary and its financial statement for the three months ended March 31, 2025 has not been reviewed by an independent auditor.

2. Subsidiaries not included in the Consolidated Financial Statements: None.

(3) Employee benefits

The defined benefit pension plans of the interim period are computed based on the year-to-date pension cost rate derived using actuarial valuation at the end of the preceding year, adjusted for significant market fluctuation, reduction, settlement or other significant one-off event.

(4) Income tax

In pursuant to the IAS 34, “Interim Financial Reporting,” paragraph B12, the Group measures and discloses the Income tax expense for the interim period.

The income tax expense is computed by multiplying the income before Income tax expense of the interim period with the effective tax rate for the full financial year best estimated by the Management, and fully recognized as the current income tax expense.

For income tax expenses recognized directly in equity or other comprehensive profit and loss items, it is measured using the appropriate tax rate expected to realize or when settled, on the temporary difference arising between the carrying amount of assets and liabilities for financial reporting purposes, and their tax bases.

5. Critical Accounting Judgments and key sources of Estimates and Assumptions on Uncertainty

In pursuant to the Preparation Regulations and the IAS 34, “Interim Financial Reporting” as endorsed by FSC, when preparing for these Consolidated Financial Statements, the Management are required to make judgment, estimates and assumptions, which will impact the adoption of accounting policies and the reporting of assets, liabilities, income, and expenses. The actual amount might differ from the estimated amount.

For the preparation of the Consolidated Financial Statements, the Management makes critical accounting judgments, estimates and assumptions on uncertainty using the accounting policies of the Group, consistent with Note 5 of the Consolidated Financial Statements for 2025.

6. Significant Accounts Disclosure

Except for the following, the details of significant accounts of these Consolidated Financial Statements does not differ with the Consolidated Financial Statements for 2025. For more information, please see Note 6 to the Consolidated Financial Statements for 2025.

(1) Cash and cash equivalents

	2026.03.31	2025.12.31	2025.03.31
Cash on hand and revolving funds	$ 2,210	2,250	2,263
Demand deposits and checking accounts	810,206	910,176	741,357
Time deposits with an initial maturity date within three months	74,500	36,900	111,039
	$ 886,916	**949,326**	**854,659**

(2) Other financial assets-current

	2026.03.31	2025.12.31	2025.03.31
Restricted deposits	$ 49,552	47,282	46,993
Domestic corporate bonds	61,111	61,137	-
Time deposits with an initial maturity date within three months	194,900	239,100	202,990
	$ 305,563	**347,519**	**249,983**
Recognized under:			
Financial assets measured at amortized cost - current	$ 244,451	286,382	249,983
Financial assets measured at amortized cost – non-current	61,111	61,137	-
	$ 305,562	**347,519**	**249,983**

In the second quarter of 2025, the Group purchased 10-year corporate bonds of Nan Shan Life Insurance Company Ltd. with par value of NTD60,000 thousand and a coupon rate of 3.75%.

The estimation of the Group is based on the collection of contractual cash flows when the asset reaches maturity. The cash flows of the financial asset consist of principal and interest on the principal amount outstanding. Therefore, it is measured at amortized cost.

Some of time deposits are pledged as guaranties. For the details, please refer to Note 8.

(3) Non-current financial assets at fair value through profit or loss

	2026.03.31	2025.12.31	2025.03.31
Financial assets at fair value through profit or loss:			
Share of non-public companies	**$ 55,785**	**53,796**	**-**

For the remeasurement at fair value through profit or loss, please refer to Note 6 (25).

(4) Non-current financial assets at fair value through other comprehensive income - non-current

	2026.03.31	2025.12.31	2025.03.31
Equity instruments at fair value through other comprehensive income			
Share of non-public companies	$ 123	123	20,197

The purpose that the Group invests in the abovementioned equity instruments is for long-term strategies but rather for trading purpose. Therefore, these equity instruments are designated as at fair value through other comprehensive income.

For the three months ended March 31, 2025 and 2024, the Group has not disposed the abovementioned strategic investments, and the accumulated profits and deficits in the period have not been reclassified within equity as well.

(5) Notes and accounts receivable (measured at amortized cost)

	2026.03.31	2025.12.31	2025.03.31
Notes receivable	$ 61,165	71,658	72,948
Accounts receivable	953,380	890,368	815,034
Less: Loss allowance	(10,967)	(10,006)	(10,408)
	1,003,578	952,020	877,574
Accounts receivable - related parties	5,168	16,527	5,718
	$ 1,008,746	968,547	883,292

The Group applies the simplified approach to make an estimation for the expected credit losses of notes and accounts receivable, i.e., measuring the lifetime expected credit losses and includes forward-looking information. Analysis of expected credit loss on notes and accounts receivable of the Group is as follows:

	2026.03.31		
	Gross carrying amount notes and accounts receivable	Weighted-average expected credit loss	Loss allowance for expected credit losses
Current	$ 891,736	0.17%	1,516
Less than 90 days overdue	78,134	4.06%	3,173
91 - 180 days overdue	38,126	9.18%	3,501
181 - 270 days overdue	4,301	12.30%	529
More than one year overdue	2,248	100.00%	2,248
	$ 1,014,545		10,967

	2025.12.31		
	Gross carrying amount notes and accounts receivable	Weighted-average expected credit loss	Loss allowance for expected credit losses
Current	$ 867,407	0.20%	1,712
Less than 90 days overdue	49,222	4.05%	1,994
91 - 180 days overdue	42,787	8.62%	3,690
More than one year overdue	2,610	100.00%	2,610
	$ 962,026		10,006

	2025.03.31		
	Gross carrying amount notes and accounts receivable	Weighted-average expected credit loss	Loss allowance for expected credit losses
Current	$ 800,967	0.20%	1,621
Less than 90 days overdue	50,014	4.87%	2,435
91 - 180 days overdue	30,571	9.29%	2,840
181 - 270 days overdue	3,242	9.99%	324
271 - 360 days overdue	232	100.00%	232
More than one year overdue	2,956	100.00%	2,956
	$ 887,982		10,408

As of March 31, 2026, and December 31 and March 31, 2025, the Group has no expected credit losses from accounts receivable - related parties. The aging analysis is as follows:

	2026.03.31	2025.12.31	2025.03.31
Current	$ 5,168	16,474	5,718
Less than 90 days overdue	-	53	-
	$ 5,168	16,527	5,718

Movements of the loss allowance for notes and accounts receivable of the Group is as follows:

	January to March 2026	January to March 2025
Beginning balance	$ 10,006	9,711
Impairment losses	961	694
Effects of exchange rate	-	3
End balance	$ 10,967	10,408

(6) Inventory

	2026.03.31	2025.12.31	2025.03.31
Raw materials	$ 68,310	72,510	69,365
Work-in-progress	37,941	43,872	36,244
Finished goods	75,000	71,143	7,792
Merchandise Inventories	716,059	662,866	783,202
Inventories in transit	9,313	42,488	8,959
	$ 906,623	**892,879**	**905,562**

Cost of goods sold relating to Inventories expenses for the current period:

	January to March 2026	January to March 2025
Cost of inventories sold	$ 869,014	804,517
Write-down of inventories	3,789	52
Gains on physical inventories	16	(160)
Sale of scraps	(6)	(11)
	$ 872,813	**804,398**

The write-down of inventories above was the amount in inventories written down to net realizable value.

(7) Non-current assets held for sale

On August 28, 2025, the Board of Directors of the Group resolved to approve the sale of a plant located in Nantun District, Taichung City, and subsequently entered into a sales agreement with a third party for a total consideration of NTD1,150,000 thousand (with VAT). Accordingly, the related land and buildings were reclassified under non-current assets held for sale. As of March 31, 2026, and December 31, 2025, the carrying amount of these assets held for sale remained at NT$422,541 thousand. For details regarding the pledge of these assets as collateral for bank credit facilities, please refer to Note 8. The consummation of this transaction is subject to approval from relevant government authorities. In the event such approval is not obtained, resulting in the failure of the transaction, the sales agreement shall be rescinded. As of May 04, 2026, the transaction is still under review by the competent authorities.

In the first quarter of 2025, CKCARE Co., Ltd., a subsidiary of the Group, planned to dispose a portion of land, and its Board of Directors resolved this proposal on April 02, 2025. As of March 31, 2025, this asset held for sale is amounted to NTD57,882 thousand. The disposal was completed in the third quarter of 2025.

(8) Subsidiaries

1. Acquisition of subsidiary – Concord BioMedical Co., Ltd.

On March 26, 2025, Board of Directors resolved that Concord Medical Co., Ltd.

("CCD"), a subsidiary of the Company, and participated in cash capital increase of Concord BioMedical Co., Ltd. ("CBM") and acquired 54.05% of ownership of CBM. Since April 01, 2025 (the acquisition date), CBM has been one of consolidated entities of the Group. CBM is engaged in the wholesale and retail of pharmaceuticals and medical equipment for animal hospitals. The purpose of CCD to acquire CBM is mainly to expand CCD's sales channels, optimize existing healthcare-related services, and diversify its medical services.

2. Changes in ownership interests in subsidiaries without loss of control

On March 05, 2026, the Group acquired an additional 12% of the ordinary shares of its subsidiary, BenQ AB DentCare Corp., for a total cash consideration of NTD12,000 thousand. This acquisition resulted in a change in the Group's ownership interest. Consequently, the Group recognized a decrease in retained earnings of NTD4,760 thousand to reflect the difference between the consideration paid and the carrying amount of the non-controlling interests acquired.

3. Subsidiaries that the Group has material non-controlling interests

Subsidiaries in which the Group has material non-controlling interests were as follows:

Subsidiary	Principal place of business/country of incorporation	Percentage of ownership and voting rights held by non-controlling interests		
		2026.03.31	2025.12.31	2025.03.31
NBHIT	Taiwan	48%	48%	48%
CCD	Taiwan	60%	60%	60%
CKCARE	Taiwan	40%	40%	40%
K2	Taiwan	60%	60%	60%

The summarized financial information of subsidiaries prepared in accordance with IFRSs endorsed by FSC was as follows. The information includes the fair value adjustment made by the Group during the acquisition as at the acquisition date:

(1) The summarized financial information of NBHIT:

	2026.03.31	2025.12.31	2025.03.31
Current assets	$ 101,595	94,289	89,162
Non-current assets	167,884	168,467	198,270
Current liabilities	(87,529)	(91,379)	(78,786)
Non-current liabilities	(55,942)	(54,589)	(76,104)
Net assets	$ 126,008	116,788	132,542
The carrying amount in non-controlling interests	$ 46,964	42,539	50,100

	January to March 2026	January to March 2025
Operating revenue	$ 93,030	87,816
Net income	$ 9,219	4,294
Other comprehensive income	-	-
Total comprehensive income	$ 9,219	4,294
Net income attributable to non-controlling interests	$ 4,425	2,061
Total comprehensive income attributable to non-controlling interests	$ 4,425	2,061

	January to March 2026	January to March 2025
Cash flows related to operating activities	$ 12,838	(2,146)
Cash flows related to investing activities	(617)	(1,786)
Cash flows related to financing activities	(8,658)	(8,723)
Net decrease in cash and cash equivalents	$ 3,563	(12,655)
Cash dividends paid to non-controlling interests	$ -	-

(2) The summarized financial information of CCD:

	2026.03.31	2025.12.31	2025.03.31
Current assets	$ 635,179	601,830	586,172
Non-current assets	650,410	661,488	576,059
Current liabilities	(390,926)	(337,322)	(290,327)
Non-current liabilities	(136,084)	(137,192)	(162,737)
Net assets	$ 758,579	788,804	709,167
The carrying amount in non-controlling interests	$ 465,601	483,752	425,502

	January to March 2026	January to March 2025
Operating revenue	$ 246,793	207,445
Net income	$ 19,775	12,916
Other comprehensive income	-	74
Total comprehensive income	$ 19,775	12,990
Net income attributable to non-controlling	$ 11,849	7,750

interests		
Total comprehensive income attributable to non-controlling interests	**$ 11,849**	**7,795**

	January to March 2026	January to March 2025
Cash flows provided by operating activities	$ 31,192	28,001
Cash flows used in investing activities	20,662	32,821
Cash flows used in financing activities	2,149	(5,029)
Net decrease in cash and cash equivalents	**$ 54,003**	**55,793**
Cash dividends paid to non-controlling interests	**$ -**	**-**

(3) The summarized financial information of CKCARE:

	2026.03.31	2025.12.31	2025.03.31
Current assets	$ 131,867	128,045	91,397
Non-current assets	100,045	103,807	177,098
Current liabilities	(71,838)	(52,653)	(90,983)
Non-current liabilities	(18,129)	(19,592)	(25,691)
Net assets	**$ 141,945**	**159,607**	**151,821**
The carrying amount in non-controlling interests	**$ 40,973**	**48,038**	**44,923**

	January to March 2026	January to March 2025
Operating revenue	**$ 85,228**	**84,876**
Net income	$ 1,240	1,097
Other comprehensive income	-	-
Total comprehensive income	**$ 1,240**	**1,097**
Net income attributable to non-controlling interests	**$ 496**	**439**
Total comprehensive income attributable to non-controlling interests	**$ 496**	**439**

	January to March 2026	January to March 2025
Cash flows provided by operating activities	$ 1,684	317
Cash flows used in investing activities	76	(635)
Cash flows used in financing activities	(2,134)	(1,496)
Net decrease in cash and cash equivalents	**$ (374)**	**(1,814)**
Cash dividends paid to non-controlling interests	**$ -**	**-**

(4) The summarized financial information of K2:

	2026.03.31	2025.12.31	2025.03.31
Current assets	$ 1,434,992	1,506,945	1,477,475
Non-current assets	445,308	445,650	427,887
Current liabilities	(856,776)	(945,877)	(791,036)
Non-current liabilities	(82,565)	(94,411)	(165,503)
Net assets	**$ 940,959**	**912,307**	**948,823**
The carrying amount in non-controlling interests	**$ 627,557**	**609,294**	**641,331**

	January to March 2026	January to March 2025
Operating revenue	**$ 529,914**	**464,944**
Net income	$ 29,115	22,760
Other comprehensive income	1,596	11,269
Total comprehensive income	**$ 30,711**	**34,029**
Net income attributable to non-controlling interests	**$ 19,665**	**16,738**
Total comprehensive income attributable to non-controlling interests	**$ 20,322**	**19,956**

	January to March 2026	January to March 2025
Cash flows provided by operating activities	$ (50,667)	(104,484)
Cash flows used in investing activities	(22,940)	(11,417)
Cash flows used in financing activities	(19,772)	57,581
Effect of changes in foreign exchange rates	(701)	3,534
Net decrease in cash and cash equivalents	$ (94,080)	(54,786)
Cash dividends paid to non-controlling interests	$ (2,059)	(4,869)

(9) Property, plant and equipment

Movements of the costs, accumulated depreciation and impairment loss of property, plant and equipment of the Group are as follows:

	Land	Buildings	Machinery	Instruments (for rental)	Leasehold improvement (for self-used and rental)	Office and other equipment	Construction in progress	Total
Cost:								
Balance as of January 01, 2026	$ 172,122	51,010	393,069	239,612	168,722	192,484	-	1,217,019
Additions	-	30	1,787	26	654	9,043	-	11,540
Disposals	-	-	(5,484)	(5,566)	(4,157)	(5,672)	-	(20,879)
Reclassification	-	-	2,650	(1,900)	-	4,263	-	5,013
Effect of changes in foreign exchange rates	-	-	(3,160)	-	171	133	-	(2,856)
Balance as of March 31, 2026	$ 172,122	51,040	388,862	232,172	165,390	200,251	-	1,209,837
Balance as of January 01, 2025	$ 346,860	364,382	385,814	264,337	158,377	173,049	1,381	1,694,200
Additions	-	-	11,087	26,742	806	2,621	-	41,256
Disposals	-	-	(2,015)	(1,476)	(3,390)	(2,029)	-	(8,910)
Effect of changes in foreign exchange rates	-	-	1,936	-	24	259	-	2,219
Reclassification	(57,882)	-	1,165	1,381	-	-	(1,381)	(56,717)
Balance as of March 31, 2025	$ 288,978	364,382	397,987	290,984	155,817	173,900	-	1,672,048
Accumulated depreciation and impairment loss:								
Balance as of January 01, 2026	$ -	31,479	270,972	131,359	104,166	130,968	-	668,944
Depreciation	-	254	10,438	9,280	4,473	5,060	-	29,505
Disposals	-	-	(5,326)	(4,726)	(4,157)	(4,772)	-	(18,981)
Reclassification	-	-	-	(443)	-	-	-	(443)
Effect of changes in foreign exchange rates	-	-	(1,828)	-	12	43	-	(1,773)
Balance as of March 31, 2026	$ -	31,733	274,256	135,470	104,494	131,299	-	677,252
Balance as of January 01, 2025	$ -	101,656	263,633	144,403	91,094	126,523	-	727,309
Depreciation	-	2,663	10,826	12,164	4,227	4,053	-	33,933
Disposals	-	-	(2,015)	(1,476)	(3,334)	(1,927)	-	(8,752)
Effect of changes in foreign exchange rates	-	-	960	-	19	145	-	1,124
Balance as of March 31, 2025	$ -	104,319	273,404	155,091	92,006	128,794	-	753,614
Carrying value:								
March 31, 2026	$ 172,122	19,307	114,606	96,702	60,896	68,952	-	532,585
January 01, 2026	$ 172,122	19,531	122,097	108,253	64,556	61,516	-	548,075
March 31, 2025	$ 288,978	260,063	124,583	135,893	63,811	45,106	-	918,434

For information on the property, plant and equipment of the Group serving as collateral for a credit line of bank loans, please see Note 8.

(10) Right-of-use assets

Movements of the costs and depreciation of buildings that the Group leases as office spaces and branch offices, and transportation equipment are as follows:

	Buildings	Transportation equipment	Total
Cost of right-of-use assets:			
Balance as of January 01, 2026	$ 349,690	22,080	371,770
Additions	21,034	647	21,681
Lease modification	42	-	42
Write-off	(16,596)	(141)	(16,737)
Effect of changes in foreign exchange rates	357	-	357
Balance as of March 31, 2026	$ 354,527	22,586	377,113
Balance as of January 01, 2025	$ 305,166	27,609	332,775
Additions	19,764	1,961	21,725
Lease modification	285	-	285
Write-off	(8,705)	(3,156)	(11,861)
Effect of changes in foreign exchange rates	551	-	551
Balance as of March 31, 2025	$ 317,061	26,414	343,475
Accumulated depreciation of right-of-use assets:			
Balance as of January 01, 2026	$ 183,065	13,147	196,212
Depreciation for the current period	20,997	1,435	22,432
Write-off	(16,596)	(141)	(16,737)
Effect of changes in foreign exchange rates	180	-	180
Balance as of March 31, 2026	$ 187,646	14,441	202,087
Balance as of January 01, 2025	$ 108,361	16,529	124,890
Depreciation for the current period	18,621	1,678	20,299
Write-off	(8,705)	(3,156)	(11,861)
Effect of changes in foreign exchange rates	245	-	245
Balance as of March 31, 2025	$ 118,522	15,051	133,573
Carrying value:			
March 31, 2026	$ 166,881	8,145	175,026
January 01, 2026	$ 166,625	8,933	175,558
March 31, 2025	$ 198,539	11,363	209,902

BENQ MEDICAL TECHNOLOGY CORP. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (continued)

(11) Investment properties

	Self-owned		Right-of-use assets	
	Land	**Buildings**	**Buildings**	**Total**
Cost:				
Balance as of January 01, 2026	$ 193,261	79,635	266,804	539,700
Balance as of March 31, 2026	**$ 193,261**	**79,635**	**266,804**	**539,700**
Balance as of January 01, 2025	$ 225,083	126,893	266,804	618,780
Additions	-	-	3,416	3,416
Balance as of March 31, 2025	**$ 225,083**	**126,893**	**270,220**	**622,196**
Accumulated depreciation:				
Balance as of January 01, 2026	$ -	27,904	139,969	167,873
Depreciation	-	973	6,035	7,008
Balance as of March 31, 2026	**$ -**	**28,877**	**146,004**	**174,881**
Balance as of January 01, 2025	$ -	36,413	116,095	152,508
Depreciation	-	1,090	6,108	7,198
Balance as of March 31, 2025	**$ -**	**37,503**	**122,203**	**159,706**
Carrying amount:				
March 31, 2026	**$ 193,261**	**50,758**	**120,800**	**364,819**
January 01, 2026	**$ 193,261**	**51,731**	**126,835**	**371,827**
March 31, 2025	**$ 225,083**	**89,390**	**148,017**	**462,490**

For investment properties leased to third parties, the proportion of land ownership, and right-of-use assets sub-leased to other parties, please see Note 6(18).

For investment properties serving as collateral for a credit line of bank loans, please see Note 8.

The fair value of the investment properties does not differ with the information revealed in Note 6(11) of the Consolidated Financial Statements for 2025.

(12) Intangible asset

1. Movements of the costs, accumulated depreciation and impairment loss of property, plant and equipment of the Group are as follows:

	Goodwill	**Computer software**	**Customer relationships and sales channels**	**Other intangible assets**	**Total**
Costs:					
Balance as of January 01, 2026	$ 278,527	31,166	217,279	69,739	596,711
Additions	-	4,432	-	-	4,432
Write-off	-	(531)	-	-	(531)
Effect of changes in foreign exchange rates	-	(4)	-	-	(4)
Balance as of March 31, 2026	**$ 278,527**	**35,063**	**217,279**	**69,739**	**600,608**
Balance as of January 01, 2025	$ 247,042	28,533	196,232	71,016	542,823
Business transfer	24,180	-	9,585	-	33,765
Additions	-	357	-	-	357
Write-off	-	(314)	-	-	(314)
Effect of changes in foreign exchange rates	-	2	-	-	2
Balance as of March 31, 2025	**$ 271,222**	**28,578**	**205,817**	**71,016**	**576,633**
Accumulated amortization:					
Balance as of January 01, 2026	$ -	23,442	112,822	33,357	169,621
Amortization	-	1,596	3,871	1,504	6,971
Write-off	-	(531)	-	-	(531)
Effect of changes in foreign exchange rates	-	(1)	-	-	(1)
Balance as of March 31, 2026	**$ -**	**24,506**	**116,693**	**34,861**	**176,060**
Balance as of January 01, 2025	$ -	20,296	98,198	29,165	147,659
Amortization	-	1,358	3,315	1,596	6,269
Write-off	-	(314)	-	-	(314)
Effect of changes in foreign exchange rates	-	1	-	-	1
Balance as of March 31, 2025	**$ -**	**21,341**	**101,513**	**30,761**	**153,615**
Carrying value:					
March 31, 2026	**$ 278,527**	**10,557**	**100,586**	**34,878**	**424,548**
January 01, 2026	**$ 278,527**	**7,724**	**104,457**	**36,382**	**427,090**
March 31, 2025	**$ 271,222**	**7,237**	**104,304**	**40,255**	**423,018**

According to IAS 36, the goodwill acquired by the Group must undergo assessment for impairment at least once a year. Pursuant to the assessment for impairment conducted by the Group on December 31, 2025, goodwill has not suffered any impairment. For details, please see Note 6(12) to the Consolidated Financial Statements for 2025. On March 31, 2026, the Group conducted an assessment based on the operating revenue meeting target for the period between January 01, 2026 and March 31, 2026, and concluded that no impairment was incurred.

2. Acquisition through business transfer

On January 02, 2025, K2, a subsidiary of the Company, acquired the assets, liabilities and business related to the rehabilitation equipment business from GIGA MEDICAL INSTRUMENT LTD. through business transfer, in amount of NTD33,765 thousand by cash. As of March 31, 2026, December 31 and March 31, 2025 the balance of payables are NTD19,478 thousand, NTD29,366 thousand, and NTD28,765 thousand recorded under other payables and other non-current liabilities, respectively.

According to IFRSs, the Group shall measure the identifiable assets and assumed liabilities at fair value on the acquisition date. The measurements are as follows:

Consideration transferred:	
Cash	$ 5,000
Account payables (under other payables)	9,685
Account payables (under other non-current liabilities)	19,080
Acquired net identifiable assets:	
Intangible asset – customer relationship	9,585
Goodwill	$ 24,180

(13) Other non-current assets

	2026.03.31	2025.12.31	2025.03.31
Prepayments for equipment	$ 3,887	6,305	18,180
Pension plan assets	14,019	13,879	11,828
Refundable Deposits	65,123	61,813	60,243
Long-term lease receivables	6,565	4,626	2,638
Long-term accounts receivable	3,859	1,361	-
Prepayments for investment	200,000	-	-
	$ 293,453	87,984	92,889

On December 29, 2025, the Board of Directors resolved to participate in the cash capital increase of Dunpin Innovation No. 5 Xinglin Co., Ltd. The Group subsequently paid the subscription price of NTD200,000 thousand on January 12, 2026, which was recognized under non-current assets – prepayments for investment. As of the reporting date, the legal registration for the capital increase is currently in progress, following the schedule established by Dunpin Innovation No. 5 Xinglin Co., Ltd.

(14) Short-term loans

1. Short-term loans are as follows:

	2026.03.31	2025.12.31	2025.03.31
Unsecured bank loans	$ 756,398	813,985	618,330
Secured bank loans	53,368	54,690	62,389
	$ 809,766	868,675	680,719
Unused credit facilities	$ 2,415,839	2,241,816	1,913,238
Interest rate bracket	1.98%~5.04%	2.00%~5.37%	1.70%~5.50%

2. Short-term note payables are as follows:

	2026.03.31	2025.12.31	2025.03.31
Short-term note payables	$ 25,984	25,852	-
Agreed repurchase price	$ 26,025	25,879	-
Agreed repurchase interest rate	2.078%	2.078%	-
Agreed repurchase date	2026.04.28	2026.01.29	-

3. For assets pledged as collateral to secure bank loans and the collateral of the short-term note payables, please see Note 8.

(15) Long-term loans

	2026.03.31	2025.12.31	2025.03.31
Secured bank loans	$ 200,000	210,000	191,578
Unsecured bank loans	808,449	563,120	713,559
Less: current portion of Long-term loans	(250,000)	(238,750)	(80,078)
	$ 758,449	534,370	825,059
Unused credit facilities	$ 897,340	1,087,798	880,000
Interest rate bracket	2.01%~4.09%	2.01%~4.09%	0.50%~4.41%

For assets pledged as collateral to secure credit line of bank loans, please see Note 8.

As described in Note 6(7), the Group has entered into a contract with a third party to sell part of the land and buildings and has reclassified the related assets under non-current assets held for sale. The aforementioned assets were pledged as collateral for long-term bank borrowings. According to the loan agreement, the bank has required the Group to repay the borrowings before the transfer date of the related property transaction. As of March 31, 2026 and December 31, 2025, the related borrowing amounting to NTD200,000 thousand and NTD210,000 thousand, respectively, have been presented under long-term borrowings due within one year.

The Group's loan contract with some of the lending banks stipulated that the agreed financial indicators must be maintained in the semi-annual and annual consolidated financial statements for the duration of the loan. The Group's consolidated financial reports for 2025 complies with the aforementioned covenant standards with the lending banks.

(16) Lease liabilities

The lease liabilities of the Group are as follows:

	2026.03.31	2025.12.31	2025.03.31
Current	$ 96,574	102,519	102,512
Non-current	$ 214,506	218,633	268,938

Please see Note 6(26) for the maturity profile of financial instruments.

Profit and loss recognized are as follows:

	January to March 2026	January to March 2025
Interest expense of lease liabilities	$ 1,554	1,703
Gain from right-of-use asset with sublease	$ (7,005)	(6,852)
Short-term lease expense	$ 4,400	3,236

Items recognized in Cash Flows Statement:

	January to March 2026	January to March 2025
Total cash outflow for leases	$ 30,714	23,580

1. Lease of buildings

Pertaining to office spaces and branch offices of the Group, the lease tenors for office spaces range from three to twenty years, and for branch offices, three to nine years, of which some of the leases have a renewal option for tenor as per the original lease contract. Part of the right-of-use assets are subleased to other parties to earn rental income. For more information, please see Note 6(11). Of which, some lease tenor of buildings or office/ warehouse is one year and thus deemed to be short-term leases. The Group chooses to adopt recognition exemption and does not recognize the relevant right-of-use assets and lease liabilities.

2. Other leases

The lease tenors of transportation equipment of the Group range from one to five years.

(17) Provision for product warranties

	2026.03.31	2025.12.31	2025.03.31
Provision for product warranty	$ 4,116	3,872	2,750

From January 01 to March 31, 2026 and 2025, the Group did not have major changes in the provision for product warranty. For details, please see Note 6(17) to Consolidated Financial Statements for 2025.

(18) Operating leases - lessor

The Group leases out its property, plant and equipment (among equipment, instruments are in majority) and investment properties. As almost all of the risk and reward of the ownership of the properties have not been transferred, the lease contracts are classified as operating leases.

The maturity analysis of the lease payments receivable showing the undiscounted lease payments after the reporting date is as follows:

	2026.03.31	2025.12.31	2025.03.31
Less than 1 year	$ 62,106	55,511	85,283
1 to 2 years	25,653	30,670	16,715
2 to 3 years	11,595	11,595	13,938
3 to 4 years	11,595	11,595	9,590
4 to 5 years	4,438	6,929	9,590
More than 5 years	8,739	9,147	11,434
Total undiscounted lease payments	**$ 124,126**	**125,447**	**146,550**

The rental income from property, plant and equipment and investment property during this period is listed as follows:

	January to March 2026	January to March 2025
Recognized as operating revenue:		
Property, plant and equipment	$ 13,360	17,835
Investment properties	8,836	8,799
	$ 22,196	**26,634**

	January to March 2026	January to March 2025
Recognized as non-operating income and expenses:		
Property, plant and equipment	$ 1,970	1,326
Investment properties	-	1,895
	$ 1,970	**3,221**

The direct operating expenses (recognized in "operating costs" and "operating expenses") incurred due to investment properties are as follows:

	January to March 2026	January to March 2025
Those generating rental income	$ 6,734	7,294
Those not generating rental income	143	131
	$ 6,877	**7,425**

(19) Employee benefits

1. Defined benefit plans

As no significant market fluctuation, reduction, settlement or other significant one-off events have occurred since the last yearly reporting date, the Group has adopted actuarial valuation as at December 31, 2025 and 2024 for pension cost measurement and pension cost for interim period disclosure.

Under the defined benefit plans of the Group, the details of pension expenses are as follows:

	January to March 2026	January to March 2025
Operating costs	$ (56)	(45)
Operating expenses	148	(142)
	$ 92	**(187)**

2. Defined contribution plans

Under the procedure for defined contribution plans of the Group, the pension expenses reported are as follows:

	January to March 2026	January to March 2025
Operating costs	$ 1,096	1,095
Operating expenses	5,875	6,113
	$ 6,971	**7,208**

(20) Income tax

1. Income tax expense

	January to March 2026	January to March 2025
Current income tax expense	**$ 22,990**	**20,096**

2. From January 01 to March 31, 2026 and 2025, no income tax had been directly recognized under equity and other comprehensive income or loss items.

3. Income tax audit

Except 2023, the Company's income tax returns for the years through 2024 have been examined and approved by the R.O.C. income tax authorities.

(21) Capital and other equity interests

Except for the following, from January 01 to March 31, 2026 and 2025, there was no major change in capital and other equity interests. For details, please see Notes 6(20) of Consolidated Financial Statements for 2025.

1. Common shares

As of March 31, 2026, and December 31 and March 31, 2025, the Company's authorized shares of common stock amounted to NTD1,500,000 thousand, with a par value of NTD10 per share, totaling 150,000 thousand shares, of which 44,566 thousand shares have been issued and outstanding.

2. Capital Surplus

	2026.03.31	2025.12.31	2025.03.31
Additional paid-in capital in excess of par issued	$ 290,309	290,309	297,921
Stock options	7,612	7,612	-
Changes in ownership interest in subsidiaries	186	186	-
	$ 298,107	298,107	297,921

Pursuant to the Company Act, any realized capital surplus is initially used to offset an accumulated deficit. The balance, if any, could be used for issuing stock dividends or distributing cash dividends based on the original shareholding ratio. Realized capital surplus includes the premium derived from the issuance of shares of stock in excess of par value and donations from stockholders received by the Group. In accordance with the Regulations Governing the Offering and Issuance of Securities by Securities Issuers, the distribution of stock dividends from capital surplus in any one year shall not exceed 10% of paid-in capital.

3. Retained earnings

According to the Article of Incorporation, any profit that the Company makes shall be first appropriated for tax payment, recovering of past losses, and 10% of the appropriation goes to legal reserve, as well as setting aside for or reversing special reserve. The remaining balance of the annual net income, together with unappropriated earnings from the beginning of the year, if any, can be distributed as dividends after the profit distribution or loss off-setting plan proposed by the Board of Directors is approved during the Shareholders' meeting. For the aforementioned earning distribution, if a cash dividend is distributed, the Board of Directors is authorized to approve and report to the Shareholders' meeting.

The Company adopts a residual dividend policy to enhance future growth and sustainable development. If profit is made, the distribution of dividends shall not be lower than 10% of the net income for the year. The dividend distribution should take into account the future development of operational scale and the cash flows need. The yearly cash dividend disbursed shall not be lower than 10% of the cash and stock dividends combined.

By resolutions of the Board meeting on March 03, 2026 and March 03, 2025, the cash dividend of earnings distribution for 2025 and 2024 is as follows:

	2025		2024	
	Dividend per share (NTD)	Amount	Dividend per share (NTD)	Amount
Dividends per share:				
Cash	$ 2.00	89,132	1.65	73,534

4. Other equity interest (net after tax)

Exchange differences on translation of foreign operations

	Foreign exchange differences arising from the translation of foreign operations	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	Total
Balance as of January 01, 2026	$ (3,545)	-	(3,545)
Foreign exchange differences arising from the translation of foreign operations	2,017	-	2,017
Balance as of March 31, 2026	$ (1,528)	-	(1,528)

	Foreign exchange differences arising from the translation of foreign operations	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	Total
Balance as of January 01, 2025	$ (2,110)	-	(2,110)
Foreign exchange differences arising from the translation of net assets in foreign operations	2,382	-	2,382
Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	-	29	29
Balance as of March 31, 2025	$ 272	29	301

5. Non-controlling interests (net after-tax)

	January to March 2026	January to March 2025
Beginning balance	$ 1,204,078	1,178,194
Equity attributable to non-controlling interests:		
Net income	37,335	27,554
Changes in ownership interest in subsidiaries	(7,240)	-
Foreign exchange differences arising from the translation of foreign operations	657	3,216
Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	-	45
Cash dividends	(39,620)	(26,869)
End balance	$ 1,195,210	1,182,140

(22) Earnings per share (EPS)

1. Basic EPS

	January to March 2026	January to March 2025
Net income attributable to shareholders of the Company	$ 12,566	22,278
Weighted-average number of ordinary shares outstanding (in thousands)	44,566	44,566
Basic EPS (NTD)	$ 0.28	0.50

2. Diluted EPS

	January to March 2026	January to March 2025
Net income attributable to shareholders of the Company	$ 12,566	22,278
Weighted-average number of ordinary shares outstanding (basic) (in thousands)	44,566	44,566
Effect of dilutive potential common stock (in thousands)		
Effect of employee bonuses	156	194
Weighted-average number of ordinary shares outstanding (diluted) (in thousands)	44,722	44,760
Diluted EPS (NTD)	$ 0.28	0.50

(23) Revenue from contracts with customers

1. Disaggregation of revenue

	January to March 2026	January to March 2025
Primary geographical markets:		
Taiwan	$ 1,002,905	880,562
Mainland China	113,924	148,084
Indonesia	66,923	70,454
Thailand	98,501	90,418
India	24,291	15,250
Others	18,063	23,190
	$ 1,324,607	1,227,958
Main products:		
Medical equipment	$ 131,775	132,976
Medical consumables	768,812	733,783
Medical services	424,020	361,199
	$ 1,324,607	1,227,958
Timing of revenue recognition:		
Revenue recognized at a point in time	$ 1,289,055	1,189,457
Revenue recognized over time	13,356	11,867
Lease income	22,196	26,634
	$ 1,324,607	1,227,958

2. Contract balances

	2026.03.31	2025.12.31	2025.03.31
Notes and accounts receivable (including related parties)	$ 1,019,713	978,553	893,700
Less: Loss allowance	(10,967)	(10,006)	(10,408)
	$ 1,008,746	968,547	883,292
Contract liabilities	$ 37,560	35,306	32,710

For disclosure on notes and accounts receivable and the related loss allowance, please refer to Note 6(5).

The changes in contract liabilities are mainly due to the timing difference between product transferred or service rendered, i.e., satisfying contractual obligations by the Group and payment made by customers.

The Group recognized revenue from the beginning balance of contract liability as of January 01, 2026 and 2025, which amounted to NTD29,536 thousand and NTD25,389 thousand for the three months ended March 31, 2026 and 2025, respectively.

(24) Remuneration to employees and Directors

According to the Articles of Incorporation, if any profit is available, 5% to 20% should be set aside as employee compensation and no more than 1% should be set aside as Directors' remuneration. However, the profit should be appropriated to offset the accumulated deficit first, if any. The aforementioned employees eligible for stock options or cash compensation may include employees of affiliated companies that meet certain conditions.

The compensation of employees for the three months ended March 31, 2026 and 2025 amounted to NTD1,253 thousand and NTD2,262 thousand, respectively; and, the remuneration of Directors amounted for the three months ended March 31, 2026 and 2025 amounting to NTD104 thousand and NTD189 thousand, respectively. The compensation of employees and the remuneration of Directors were estimated by multiplying pre-tax income prior to being deducted by remuneration to employees and Directors of the period with the distribution percentage of remuneration to employees and Directors. The compensation and remuneration were classified as the Costs of revenue or expenses for the period. If the actual disbursement in the following year differs from the estimated amount, the difference is treated as change in accounting estimation, and recognized in the profit and loss in the next annual period.

The estimated amounts of employee compensation for 2025 and 2024 amounted to NTD7,958 thousand and NTD10,570 thousand, respectively; and the estimated amounts of director remuneration amounted to NTD663 thousand and NTD881 thousand, respectively. The aforementioned amounts did not differ from the employee compensation and director remuneration approved by the Board, and were all disbursed in cash. For details, please see the Market Observation Post System.

(25) Non-operating income and loss

1. Interest income

	January to March 2026	January to March 2025
Interest income from bank deposits	$ 2,287	1,718

2. Other income

	January to March 2026	January to March 2025
Rental income	$ 1,970	3,221
Dividend income	4,864	-
Others	1,301	720
	$ 8,135	3,941

3. Other gains and losses

	January to March 2026	January to March 2025
Gains on disposal of property, plant and equipment	$ 74	384
Net foreign currency exchange gains	2,579	1,707
Gains on financial assets measured at fair value through profit or loss	1,989	-
Gains on lease modification	30	11
	$ 4,672	2,102

4. Financing costs

	January to March 2026	January to March 2025
Interest expense of bank loans	$ 10,009	8,980
Other financial expense	112	-
Financial expense of lease liabilities	1,554	1,703
	$ 11,675	10,683

(26) Financial instruments

Except for the following, the fair value of the financial instruments and the credit, liquidity and market risks exposed due to the financial instruments have no significant changes. For details, please see Notes 6(26) and (27) of Consolidated Financial Statements for 2025.

1. Categories of financial instruments

(1) Financial assets

	2026.03.31	2025.12.31	2025.03.31
Financial assets measured at fair value through profit or loss	$ 55,785	53,796	-
Financial assets at fair value through other comprehensive income	123	123	20,197
Financial assets at amortized cost:			
Cash and cash equivalents	886,916	949,326	854,659
Notes and accounts receivable and other receivables (including related parties)	1,022,910	977,811	892,126
Financial assets at amortized cost (current and non-current)	305,562	347,519	249,983
Other non-current assets - refundable deposits	65,123	61,813	60,243
Other non-current assets - long-term receivables	3,859	1,361	-
Other non-current assets - long-term lease receivables	6,565	4,626	2,638
Subtotal	2,290,935	2,342,456	2,059,649
	$ 2,346,843	2,396,375	2,079,846

(2) Financial liabilities

	2026.03.31	2025.12.31	2025.03.31
Financial liabilities at amortized cost:			
Short-term loans	$ 809,766	868,675	680,719
Short-term note payables	25,984	25,852	-
Notes and accounts payable and other payables (including related parties)	995,242	941,046	899,891
Lease liabilities (current and non-current)	311,080	321,152	371,450
Long-term loans (including current portion)	1,008,449	773,120	905,137
Guarantee deposit received	11,595	12,848	6,768
Other non-current liabilities- long-term other payables	9,473	19,080	19,080
	$ 3,171,589	2,961,773	2,883,045

2. Fair value

(1) Financial instruments not at fair value

The Management of the Group opines that carrying values of financial assets and liabilities of the Group measured at amortized cost in the consolidated financial statements are similar to their fair values.

(2) Financial instruments at fair value

The following financial instruments are measured at fair value on a recurring basis. The following table provides analysis of financial instrument at fair value subsequent to the initial recognition according to observable inputs from level 1 to 3.

The definitions of fair value hierarchy are as follows:

A. Level 1 inputs: Similar assets or liabilities with quoted prices in an active market (unadjusted).

B. Level 2 inputs: Apart from quoted prices in level 1 inputs, the inputs for assets or liabilities are directly (i.e., prices) or indirectly (i.e. derived from prices) observable.

C. Level 3 inputs: The inputs for assets or liabilities are not based on observable market information (non-observable parameters).

	2026.03.31			
	Fair value			
	Level 1 inputs	Level 2 inputs	Level 3 inputs	Total
Financial assets at fair value through profit or loss:				
Unlisted company shares	$ -	-	55,785	55,785
Financial assets at fair value through other comprehensive income:				
Share of non-public companies	$ -	-	123	123

	2025.12.31			
	Fair value			
	Level 1 inputs	Level 2 inputs	Level 3 inputs	Total
Financial assets at fair value through profit or loss:				
Unlisted company shares	$ -	-	53,796	53,796
Financial assets at fair value through other comprehensive income:				
Share of non-public companies	$ -	-	123	123

	2025.03.31			
	Fair value			
	Level 1 inputs	Level 2 inputs	Level 3 inputs	Total
Financial assets at fair value through profit or loss:				
Share of non-public companies	$ -	-	20,197	20,197

There is no movement among fair value hierarchies from January 01 to March 31, 2026 and 2025.

(3) Movement of Level 3

	Financial assets at fair value through profit or loss	
	January to March 2026	January to March 2025
Beginning balance	$ 53,796	-
Total gains and losses		
Through profit or loss	1,989	-
End balance	**$ 55,785**	-

	Financial assets at fair value through other comprehensive income	
	January to March 2026	**January to March 2025**
Beginning balance	$ 123	20,123
Through profit or loss	-	74
End balance	**$ 123**	**20,197**

(4) Valuation technique and inputs of financial instruments at fair value

Fair value of level 3 inputs for share of non-public companies are fair value measured using the market approach. The determination takes into consideration recent financing activities and net worth of the Company, market condition and other economic indicators. Meanwhile, material and yet unobservable inputs are mainly liquidity discount. Nevertheless, as the potential fluctuation of liquidity discount shall not give rise to material potential financial influence, the quantification information is deemed not to be necessary for disclosure.

3. Credit risk

Credit risk is the risk of financial loss to the Group when a counterparty of a financial asset transaction fails to meet its contractual obligations. It arises primarily from bank deposits (including bank deposits listed under financial assets measured at amortized cost - current), accounts receivable and other financial assets. The maximum exposure to credit risk amounts to the carrying amount in the Group's financial assets.

The Group's bank deposits are in reputable financial institutions, resulting in no significant credit risk.

The Group has established a credit policy and determined the credit limit of specific customers according to their financial status pursuant to the policy. As of March 31, 2026 and December 31 and March 31, 2025, 17%, 20%, and 26% of the Group's notes and accounts receivables were concentrated on three customers, respectively. The Group also evaluated the customer financial condition on a regular basis to reduce credit risk. For information on maximum exposure to credit risk that arises from notes and accounts receivable, please see Note 6(5).

Other financial assets measured at amortized cost include bank time deposits, investments in corporate bonds, and other receivables (bank time deposits and investments in corporate bonds are recognized in financial assets measured at amortized cost - current; for details, please refer to Note 6(2)). The above are all financial assets with low credit risk; therefore, the allowance for loss for the period is measured based on the 12-month expected credit loss amount. The balances as of March 31, 2026 and December 31 and March 31, 2025 amounted to NTD319,726 thousand, NTD356,783 thousand, and NTD311,656 thousand, respectively. There were no expected credit losses after assessment.

4. Liquidity risk

Liquidity risk is the risk that arises when the Group has difficulty in settling its financial liabilities either by cash or other financial assets. The Group manages its liquidity risk by monitoring the current and medium to long-term cash demand regularly and maintaining adequate cash and cash equivalents and line of credit at banking facilities. As at March 31, 2026, and December 31 and March 31, 2025, the unused credit facilities of the Group amounted to NTD3,313,179 thousand, NTD3,329,614 thousand, and NTD2,793,238 thousand, respectively.

The following table summarizes the maturity profile of the Group's financial liabilities based on the earliest repayment dates and is prepared according to the contractual undiscounted payments.

	Contractual cash flows	Within 6 months	6-12 months	1-2 years	2-5 years	More than 5 years
March 31, 2026						
Non-derivative financial liabilities:						
Short-term loans	$ 814,824	705,131	109,693	-	-	-
Short-term notes payable	26,025	26,025	-	-	-	-
Long-term loans (including current portion)	1,040,866	251,972	16,006	598,307	174,581	-
Notes and accounts payable and other payables (including related parties)	995,242	995,242	-	-	-	-
Other non-current liabilities	10,000	-	-	10,000	-	-
Guarantee deposit received	11,595	261	162	14	11,158	-
Lease liabilities	348,395	62,795	56,083	77,622	111,874	40,021
	$ 3,246,947	2,041,426	181,944	685,943	297,613	40,021
December 31, 2025						
Non-derivative financial liabilities						
Short-term loans	$ 875,998	626,234	249,764	-	-	-
Long-term loans (including current portion)	797,910	242,061	9,803	432,995	113,051	-
Short-term notes payable	25,879	25,879	-	-	-	-
Notes and accounts payable and other payables (including related parties)	941,046	941,046	-	-	-	-
Other non-current liabilities	20,000	-	-	10,000	10,000	-
Guarantee deposit received	12,848	358	92	40	12,358	-
Lease liabilities	338,514	59,806	47,480	76,400	111,821	43,007
	$ 3,012,195	1,895,384	307,139	519,435	247,230	43,007
March 31, 2025						
Non-derivative financial liabilities						
Short-term loans	$ 684,368	646,113	38,255	-	-	-
Long-term loans (including current portion)	940,627	63,646	34,773	517,581	324,627	-
Notes and accounts payable and other payables (including related parties)	899,891	899,891	-	-	-	-
Other non-current liabilities	20,000	-	-	10,000	10,000	-
Guarantee deposit received	6,768	250	115	25	6,378	-
Lease liabilities	391,388	54,125	52,540	87,477	133,863	63,383
	$ 2,943,042	1,664,025	125,683	615,083	474,868	63,383

The Group does not expect that the cash flows included in the maturity analysis will occur significantly earlier or at significantly different amounts.

5. Market risk

(1) Foreign exchange risk

The foreign exchange risk of the Group is mainly due to translation differences, gains, or losses of cash and cash equivalents, accounts receivable (including related-party transactions), accounts payable (including related-party transactions), other receivables (including related-party transactions), other payables (including related-party transactions), and bank loans that are not denominated in functional currencies. The carrying amounts of significant monetary assets and liabilities that are not denominated in functional currencies at the reporting date (including monetary items eliminated in the consolidated financial statements that are not denominated in functional currencies) and the related sensitivity analysis are as follows:

Unit : in thousand

	2026.03.31				
	Foreign currency	**Exchange rate**	**NTD**	**Change in exchange rate**	**Effect of profit or loss**
Financial assets					
USD	$ 3,207	31.995	102,608	1%	1,026
EUR	19	36.705	697	1%	7
RMB	166,481	0.200	33,296	1%	333
JPY					
Financial liabilities	2,581	31.995	82,579	1%	826
USD	60	36.705	2,202	1%	22
EUR	$ 3,207	31.995	102,608	1%	1,026
JPY	19	36.705	697	1%	7

	2025.12.31				
	Foreign currency	**Exchange rate**	**NTD**	**Change in exchange rate**	**Effect of profit or loss**
Financial assets					
USD	$ 3,164	31.430	99,445	1%	994
EUR	62	36.896	2,288	1%	23
RMB	570	4.495	2,562	1%	26
JPY	78,600	0.201	15,799	1%	158
Financial liabilities					
USD	3,052	31.430	95,924	1%	959
EUR	522	36.896	19,260	1%	193
JPY	40,272	0.201	8,095	1%	81

	2025.03.31				
	Foreign currency	**Exchange rate**	**NTD**	**Change in exchange rate**	**Effect of profit or loss**
Financial assets					
USD	$ 6,321	33.205	209,889	1%	2,099
EUR	9	35.964	324	1%	3
RMB	224	4.579	1,026	1%	10
JPY	328,444	0.223	73,243	1%	732
Financial liabilities					
USD	5,405	33.205	179,473	1%	1,795
EUR	283	35.964	10,178	1%	102
JPY	264,596	0.223	59,005	1%	590

Since the Group has many kinds of functional currencies, the information on foreign exchange gain (loss) on monetary items is disclosed by the total amount. For the three months ended on March 31, 2026 and 2025, the foreign exchange gain (loss) (including realized and unrealized portions) refer to Note 6(25).

(2) Interest rate risk

The Group's bank loans carry floating interest rates. To mitigate the interest rate risk, the Group periodically assesses the interest rates of different banks and currencies and maintains good relationships with financial institutions for a lower financing cost. The Group also strengthens the management of working capital to reduce the dependence on bank loans and diversify the risk arising from the fluctuation of interest rates.

The following sensitivity analysis is based on the risk exposure to floating-interest-rate of bank loans as at the reporting date. The sensitivity analysis assumes the liabilities recorded as of the reporting date had been outstanding for the entire period. The internal reporting of the Group to the Management on the fluctuation of 1% increase or decrease in yearly interest rate also represents the evaluation of the Management on the reasonable changes of the interest rate.

If the yearly interest rate increases/decreases 1%, all variables remained unchanged, the income before tax of the Group for January 01 to March 31, 2026 and 2025 would increase/decrease NTD4,546 thousand and NTD3,965 thousand, respectively.

(3) Price risk in equity instruments

The purpose that the Group invests in equity stocks of non-public companies is for long-term strategies, and the Group does not trade these stocks actively. The sensitivity analysis for the equity instruments is based on the change in fair value as of the reporting date. If the price of the equity instruments increases/decreases 5%, the other comprehensive incomes for January 01 to March 31, 2026 and 2025 would increase/decrease NTD2,795 thousand and NTD1,010 thousand, respectively.

(27) Financial risk management

The goal and policy of the financial risk management of the Group and the disclosure made at Notes 6(27) of Consolidated Financial Statements for 2025 undergo no significant changes.

(28) Capital management

The goal, policy, and procedures of capital management of the Group does not differ from the disclosure made at the Consolidated Financial Statements for 2025. For details, please see Notes 6(28) of Consolidated Financial Statements for 2025.

(29) Investing and financing activities not affecting current cash flow

1. For the acquisition of right-of-use assets and investment properties through leases, please see Note 6(10) and (11).

2. Investing activities partially paid by cash

	January to March 2026
Beginning balance of other payables- business transfer	$ 10,286
Beginning balance of other non-current liabilities-business transfer	19,080
add: interest expense	112
minus: balance of other payables- business transfer	(10,005)
balance of other non-current liabilities-business transfer	(9,473)
Net cash flow used in acquisition of business transfer	$ 10,000

	January to March 2026
Purchase price of business transfer	$ 33,765
minus: balance of other payables- business transfer	(9,685)
balance of other non-current liabilities-business transfer	(19,080)
Net cash flow used in acquisition of business transfer	$ 5,000

	January to March 2026
Beginning balance of payables-cash outflow in acquisition of subsidiaries	$ 21,262
Net cash flow used in acquisition of subsidiaries	$ 21,262

3. Reconciliation of liabilities arising from financing activities were as follows:

			Non-cash changes		
	2026.01.01	Cash flows	Change of lease	Other change	2026.03.31
Short-term loans	$ 868,675	(58,909)	-	-	809,766
Short-term notes payable	25,852	-	-	132	25,984
Long-term loans (including current portion)	773,120	235,329	-	-	1,008,449
Lease liabilities	321,152	(31,765)	21,693	-	311,080
Guarantee deposit received	12,848	(1,253)	-	-	11,595
Liabilities from financing activities	$ 2,001,647	143,402	21,693	132	2,166,874

			Non-cash changes	
	2025.01.01	Cash flows	Change of lease	2025.03.31
Short-term loans	$ 580,703	100,016	-	680,719
Long-term loans (including current portion)	953,776	(48,639)	-	905,137
Lease liabilities	371,528	(25,493)	25,415	371,450
Guarantee deposit received	6,891	(123)	-	6,768
Liabilities from financing activities	$ 1,912,898	25,761	25,415	1,964,074

7. Related-party Transactions

(1) Parent company and ultimate controlling company

BenQ Corporation is the parent company of the Company. Qisda Corporation is the ultimate controlling company of the Company. Its indirect ownership of the outstanding common stocks amounts to 54.96%, and its consolidated financial statements are made available to the public.

(2) Related party name and categories

During the reporting period of these Consolidated Financial Statements, the related parties that transacted with the Group were as follows:

Name of related party	Relationship with the Group
Qisda Corporation (Qisda)	Ultimate controlling company of the Group
BenQ Corporation (BenQ)	The parent company of the Group
Other related parties:	
BenQ Technology (Shanghai) Co., Ltd.	Subsidiary of BenQ
Darly2 Venture, Inc.	Subsidiary of BenQ
BenQ Materials Corporation (BMC)	Subsidiary of Qisda
BenQ Materials (Suzhou) Corp.	Subsidiary of BMC
Sigma Medical Supplies Corporation	Subsidiary of BMC
Web-Pro Materials Corporation (formerly known as WEB-PRO Corp.)	Subsidiary of BMC
Qisda (Suzhou) Co., Ltd.	Subsidiary of Qisda
BENQ Asia Pacific Corp.	Subsidiary of Qisda
Nanjing BenQ Hospital Co., Ltd.	Subsidiary of Qisda
Suzhou BenQ Hospital Co., Ltd.	Subsidiary of Qisda
BenQ Medical (Shanghai) Co., Ltd	Subsidiary of Qisda
BenQ Dialysis Technology Corp.	Subsidiary of Qisda
Ace Pillar Co., Ltd.	Subsidiary of Qisda
Standard Technology Corporation	Subsidiary of Qisda
Tekpak Corporation	Subsidiary of Qisda
Golden Spirit Co., Ltd. (GSC)	Subsidiary of Qisda
Naisen Kelin Industry Co., Ltd.	Subsidiary of GSC
Data Image Corporation	Subsidiary of Qisda
Aewin Technologies Co., Ltd.	Subsidiary of Qisda
E-strong Medical Technology Co., Ltd.	Subsidiary of Qisda
Simula Technology Inc.	Subsidiary of Qisda
Action Star Technology Co., Ltd.	Subsidiary of Qisda
Interactive Digital Technologies Inc.	Subsidiary of Qisda
ACE Energy Co., Ltd.	Subsidiary of Qisda
Metaage Corporation (MTG)	Subsidiary of Qisda
Epic Cloud Co., Ltd.	Subsidiary of MTG

Name of related party	Relationship with the Group
Global Intelligence Network Co., Ltd.	Subsidiary of MTG
DSI Group co., Ltd.	Subsidiary of MTG
AdvancedTek International Corp.	Subsidiary of MTG
DKABio Co., Ltd.	Subsidiary of MTG
Metaguru Corporation	Subsidiary of MTG
Partner Tech Corporation (PTT)	Subsidiary of Qisda
WiXtar Corporation	Subsidiary of PTT
Partner Tech Asia Pacific Corporation	Subsidiary of PTT
Alpha Networks Inc.	Subsidiary of Qisda
Diva Laboratories Ltd.	Subsidiary of Qisda
Transnet Corporation	Subsidiary of Qisda
Bigmin Bio-Tech Company Ltd.	Subsidiary of Qisda
Darad Innovation Corporation	Subsidiary of Darfon
Chan Guare Industry Co., Ltd.	Subsidiary of Qisda
Norbel Baby Co., Ltd.	Subsidiary of Qisda
Q.S.Control Corporation	Associates of Qisda
Marketop Smart Solutions Co., Ltd.	Affiliates of Qisda
Darad Innovation Corporation	Associate indirectly held by Qisda
BenQ Foundation	Substantive related party of Qisda
Darwin Precisions Corporation	Subsidiary of AUO (Note)
AUO Education Service Corp.	Subsidiary of AUO (Note)

(Note): AU Optronics is a corporate director of Qisda.

(3) Related-party transactions

1. Operating revenues

The sales to related parties were as follows:

	January to March 2026	January to March 2025
Ultimate controlling company	$ 156	35
Other related parties	1,590	2,122
	$ 1,746	2,157

Except for some merchandise with different specifications, the sales to related parties by the Group were not comparable to the sales prices for third-party customers. For the other transactions, there were no significant differences between the sales prices for related parties and those for third-party customers. Meanwhile, the credit period did not significantly differ from normal sales.

2. Purchases

The purchases made by the Group with related parties were as follows:

	January to March 2026	January to March 2025
Ultimate controlling company	$ 14,546	12,326
Other related parties	17,937	19,575
	$ 32,483	**31,901**

The conditions of procurement between the Group and the related parties above do not differ significantly from transactions with an external party.

3. Leases

(1) The Group leases factory plant and offices from Qisda and other related parties and the rental was set by referring to the rental market of the area. During January 01 to March, 2025 and 2024, the Group leases one of the offices from Qisda and recognizes NTD0 thousand and NTD549 thousand as the right-of-use asset and lease liability, respectively. The lease-related interest expense recognized for the three months ended March 31, 2026 and 2025 amounted to NTD41 thousand and NTD96 thousand, respectively. As of March 31, 2026 and December 31 and March 31, 2025, the lease liabilities amounted to NTD6,283 thousand, NTD9,399 thousand and NTD18,042 thousand, respectively.

(2) The Group has leased offices from Qisda and other related parties, and the agreements are short-term leases. The Group opted for exemption of recognition and did not recognize the related right-of-use assets and lease liabilities. The rental expense recognized for the three months ended March 31, 2026 and 2025 amounted to NTD122 thousand and NTD147 thousand, respectively. On March 31, 2026 and 2025, the related payables are classified under other payables.

4. Acquisition and disposal of property, plant, and equipment

For January 01 to March 31, 2025, the Group purchased fixed assets from other related parties which amounted to NTD1,599 thousand. As of March 31, 2025, the related payables are classified under other payables.

5. Operating costs and expenses

The operating costs and the operating expenses related to the services, sundry purchases, disbursements, and miscellaneous expenses provided by the ultimate controlling company, the parent company, joint venture, and other related parties are as follows:

Account	Related-party	January to March 2026	January to March 2025
Operating costs	Ultimate controlling company	$ 548	550
	Other related parties	29	22
		577	572
Operating expenses	Ultimate controlling company	2,387	2,618
	Parent company	156	162
	Other related parties	1,381	1,138
		3,924	3,918
		$ 4,501	4,490

6. Receivables from related parties

The receivables from related parties of the Group are as follows:

Account	Related-party	2026.03.31	2025.12.31	2025.03.31
Accounts receivable - related parties	Ultimate controlling company	$ 22	154	15
Accounts receivable - related parties	Other related parties	5,146	16,373	5,703
		$ 5,168	16,527	5,718

7. Payables to related parties

The payables to related parties of the Group are as follows:

Account	Related-party	2026.03.31	2025.12.31	2025.03.31
Accounts payable - related parties	Ultimate controlling company	$ 10,474	9,948	9,885
Accounts payable - related parties	Other related parties	23,611	25,553	27,309
		34,085	35,501	37,194
Other payables - related parties	Ultimate controlling company	2,676	4,054	4,952
Other payables - related parties	Parent company	514	44	724
Other payables - related parties	Other related parties	1,048	423	1,184
		4,238	4,521	6,860
Lease liabilities - current	Ultimate controlling company	5,111	7,543	12,107
Lease liabilities - non-current	Ultimate controlling company	1,172	1,856	5,935
		6,283	9,399	18,042
		$ 44,606	49,421	62,096

(4) Transaction with key management personnel

Compensation for key management personnel:

	January to March 2026	January to March 2025
Short-term employee benefits	$ 3,832	4,228
Post-employment benefits	63	63
	$ 3,895	4,291

8. Pledged Assets

The carrying value of pledged assets of the Group is as follows:

Pledged Assets	Pledged to secure	2026.03.31	2025.12.31	2025.03.31
Financial assets measured at amortized cost - current	Performance bond	$ 49,551	47,282	46,993
Non-current assets held for sale	Credit lines of bank loans	422,541	422,541	-
Land and buildings	Credit lines of bank loans	75,791	75,968	428,390
Investment Property	Credit lines of bank loans	163,453	163,822	239,284
Financial assets measured at amortized cost – non-current	Short-term note payables	30,553	30,566	-
		$ 741,889	740,179	714,667

9. Significant Contingent Liabilities and Unrecognized Contractual Commitments

(1) Significant unrecognized contractual commitments:

	2026.03.31	2025.12.31	2025.03.31
Letter of credit issued and yet to be used	$ 43,000	40,000	39,765

10. Significant Loss from Disaster: None.

11. Significant Subsequent Events: None.

12. Others

(1) Employee benefits, depreciation, and amortization are as follows:

Item / Category	January to March 2026			January to March 2025		
	Operating Costs	Operating expenses	Total	Operating Costs	Operating expenses	Total
Employee benefits						
Salaries	24,170	151,692	175,862	24,547	143,152	167,699
Insurance	2,555	14,100	16,655	2,603	13,635	16,238
Pension	1,040	6,023	7,063	1,050	5,971	7,021
Other employee benefits	1,625	7,389	9,014	1,679	8,580	10,259
Depreciation	24,338	34,607	58,945	29,218	32,212	61,430
Amortization	404	6,567	6,971	475	5,794	6,269

(2) The impact of seasonal or cyclical factors is not material to the operation of the Group.

13. Additional Disclosures

(1) Information on significant transactions

For January 01 to March 31, 2026, according to the Preparation Regulations, the information on significant transactions is as follows:

1. Financing provided to other parties: None.
2. Guarantees and endorsements provided to other parties: None.
3. Marketable securities held at the reporting date (excluding investments in subsidiaries, associates, and joint ventures):

BENQ MEDICAL TECHNOLOGY CORP. AND SUBSIDIARIES
Notes to Consolidated Financial Statements (continued)

Unit: NTD thousand/thousand shares

Holding company	Type and name of securities	Relationship with securities issuer	Accounting item	End of period				Peek during the period		Note
				Shares	Carrying amount	Shareholding Percentage	Fair value	Shares	Shareholding Percentage	
Concord Medical Co., Ltd.	Fong Huang 8 Innovation Corporation	-	Financial assets measured at fair value through profit or loss - non-current	2,000	22,786	9.76 %	22,786	2,000	9.76 %	
Concord Medical Co., Ltd.	Fong Huang 7 Innovation Corporation	-	Financial assets measured at fair value through profit or loss - non-current	2,500	32,999	1.11 %	32,999	2,500	1.11 %	
Concord Medical Co., Ltd.	Nan Shan Life Insurance Co., Ltd. Corporate Bonds	-	Financial assets at amortized cost - non-current	-	61,111	-	61,111	-	-	

4. Total purchases from and sales to related parties which exceed $100 million or 20% of the paid-in capital: None.
5. Receivables from related parties which exceed $100 million or 20% of the paid-in capital: None.
6. Business relationships and significant intercompany transactions:

				Transaction details (Note 3)			
Number (Note 1)	Company	Counterparty	Relationship (Note 2)	Account	Amount	Transaction terms	% of total consolidated net revenue or total assets(Note 4)
1	K2	K2SH	1	Operating revenue	60,230	OA 90	5%

Note 1: Parties to the intercompany transactions are identified and numbered as follow:
1. "0" represents the Company
2. Subsidiaries are numbered from "1".

Note 2: Nature of relationships of the intercompany transactions are numbered as follow:
"1" represents the transactions from the parent company to subsidiary.
"2" represents the transactions from subsidiary to the parent company.
"3" represents the transactions between subsidiaries.

Note 3: Intercompany relationships and significant intercompany transactions are disclosed only for the amounts that exceed 1% of consolidated net revenue or total assets. The corresponding purchased and accounts payables are not disclosed.

Note 4: Transactions divided by consolidated operating revenues or consolidated total assets

Note 5: The above intercompany transactions have been eliminated when preparing the consolidated financial statements

(2) Information on investees:

For January 01 to March 31, 2026, the information on investees is as follows (excluding investments in Mainland China):

Unit: thousand shares

Name of investor	Name of investee	Location	Main Businesses and Products	Original investment Amount		Balance as of March 31, 2026			Net income (loss) of the investee	Investment income	Note
				March 31, 2026	December 31, 2025	Shares	Percentage of Ownership	Carrying amount			
The Company	AsiaConnect International Co., Ltd.	Taiwan	Wholesaling and retailing of medical equipment and information software	21,984	21,984	1,995	99.75%	24,678	258	257	(Note)
The Company	Lily Medical Corporation	Taiwan	Wholesaling and retailing of medical consumables and equipment	185,000	185,000	10,000	100.00%	245,118	5,078	5,173	(Note)
The Company	BenQ AB DentCare Corporation	Taiwan	Wholesaling and retailing of medical consumables and equipment	100,000	88,000	10,000	100.00%	59,620	(1,269)	(1,185)	(Note)
The Company	BenQ Healthcare Corporation	Taiwan	Wholesaling and retailing of medical consumables and equipment	100,000	100,000	10,000	100.00%	194,529	8,920	8,920	(Note)
The Company	Eastech Co., Ltd	Taiwan	Wholesaling and retailing of medical consumables and equipment	20,300	20,300	700	70.00%	41,198	3,277	2,306	(Note)
The Company	Concord Medical Co., Ltd.	Taiwan	Sales of medical drugs, leasing of medical equipment and providing management consultation services	190,000	190,000	13,333	40.00%	292,969	20,044	7,926	(Note)
The Company	K2 International Medical Inc.	Taiwan	Sales of medical consumables and equipment	390,000	390,000	7,800	39.00%	305,584	23,626	9,214	(Note)
CCD	Concord HealthCare Co., Ltd.	Taiwan	Wholesaling and retailing of medical consumables and equipment and provision of management consulting services	119,984	119,984	12,000	100.00%	124,568	713	-	(Note)

Name of investor	Name of investee	Location	Main Businesses and Products	Original investment Amount		Balance as of March 31, 2026			Net income (loss) of the investee	Investment income	Note
				March 31, 2026	December 31, 2025	Shares	Percentage of Ownership	Carrying amount			
CCD	Concord BioMedical Co., Ltd.	Taiwan	Wholesale and retail of animal pharmaceuticals and medical devices	3,000	3,000	300	54.05%	2,911	(507)	-	(Note)
CCD	Concord BioTech Co., Ltd.	Taiwan	Consulting services for medical laboratories, centralized procurement services, and equipment placement	31,000	31,000	3,100	50.82%	31,491	620	-	(Note)
BHS	New Best Hearing International Trade Co., Ltd.	Taiwan	Wholesaling and retailing of medical consumables and equipment	59,280	59,280	1,092	52.00%	79,044	9,962	-	(Note)
BHS	CKCARE Co., Ltd.	Taiwan	Retail of medical devices, over-the-counter drugs, and health supplements.	105,300	105,300	4,362	60.00%	100,973	1,809	-	(Note)
K2	K2 Medical (Thailand) Co., Ltd.	Thailand	Sales of medical consumables and equipment	61,395	61,395	-	79.66%	118,425	11,774	-	(Note)
K2	PT. Frismed Hoslab Indonesia	Indonesia	Blood banking equipment and supplies	257,728	257,728	12	67.00%	300,397	6,599	-	(Note)
K2	Era Bioteq Enterprise Co., Ltd.	Taiwan	Sales of endoscopic consumables and equipment	133,005	133,005	2,700	60.00%	146,342	3,790	-	(Note)
K2 Thailand	K2 BioMedical Co., Ltd.	Thailand	Sale of medical consumables and equipment	4,506	4,506	-	99.00%	8,674	3,352	-	(Note)
ACI	K2 International Medical Inc.	Taiwan	Sales of medical consumables and equipment	10,000	10,000	200	1.00%	7,835	23,626	-	(Note)

(Note) The above intercompany transactions have been eliminated when preparing the Consolidated Financial Statements.

(3) Information on investments in Mainland China:

1. Name, main businesses, and products of the investee in Mainland China:

Unit: NTD thousand / foreign currency in thousand

Investee in Mainland China	Main Businesses and Products	Total paid-in capital	Method of investment (Note 1)	Accumulated outflow of investment from Taiwan as of January 01, 2026 (Note 2)	Investment amount of outflow or inflow		Accumulated outflow of investment from Taiwan as of March 31, 2026	Net income (loss) of the investee	Percentage of ownership of direct and indirect investment	Investment income (loss)	Carrying value as of March 31, 2026	Accumulated inward remittance of earnings as of March 31, 2026
					Outflow	Inflow						
BenQ Medical Technology (Shanghai) Ltd.	Agency of international and entrepot trade business	63,990 (USD 2,000)	(1)	63,990 (USD 1,000)	-	-	63,990 (USD 2,000)	(3,877)	100.00%	(3,877)	27,296 (Note 3 and Note 5)	-
BenQ Smart Healthcare (Shanghai) Co.,Ltd.	Wholesaling and retailing of medical consumables and equipment	6,719 (USD 210)	(Note 6)	-	-	-	-	314	100.00%	314	1,077 (Note 3 and Note 5)	-
K2 (Shanghai) International Medical Inc.	Sales of medical consumables and equipment	39,994 (USD 1,250)	(1)	61,846 (USD 1,933)	-	-	61,846 (USD 1,933)	5,087	40.00%	2,035	63,655 (Note 3 and Note 5)	-

(Note 1) (1) Direct investment in Mainland China companies; (2) Indirect investment in Mainland China through a holding company established in a third country.
(Note 2) The amounts above are translated as per the following exchange rates: USD: NTD = 1:31.995.
(Note 3) The recognition basis for the investment profit or loss is based on unaudited financial statements prepared by investee companies.
(Note 4) The company is a limited liability company and shareholding information is unavailable.
(Note 5) The intercompany transactions above have been eliminated when preparing the Consolidated Financial Statements.
(Note 6) Invested by BenQ Medical Technology (Shanghai) Ltd. in BenQ Smart Healthcare (Shanghai) Co., Ltd..

2. Limits on investments in Mainland China:

Unit: NTD thousand/foreign currency in thousand

Company Name	Accumulated investment in Mainland China as of March 31, 2026	Investment amounts authorized by Investment Commission, MOEA	Upper Limit on Investment authorized by Investment Commission, MOEA
The Company	63,990 (USD2,000)	63,990 (USD2,000)	628,419
K2	61,846 (USD1,933)	61,846 (USD1,933)	412,808

3. Significant transactions with investee companies in Mainland China:

   For the significant transactions between the Group and the investee companies directly or indirectly (which have been eliminated when preparing the Consolidated Financial Statements) in the three months ended March 31, 2026, please refer to "(1) Information on significant transactions".

4. Provision of endorsement and guarantee, or collateral for direct investment in Mainland China or through a holding company established in a third country: None.
5. Provision of funds and loans for direct investment in Mainland China or through a holding company established in a third country: None.
6. Other significant transactions that affect the profit and loss or financial condition of the current period: None.

14. Segment Information

(1) General information

The reportable segments of operational divisions of the Group consist of R&D and manufacturing divisions, as well as medical services divisions. R&D and manufacturing divisions mainly engage in manufacturing, assembly, maintenance, and repair of medical equipment and facilities. The main business activities of medical services divisions are the wholesaling and retailing of medical devices, medical equipment, medication and health supplements, as well as the provision of leasing, management and consultation services for medical devices.

The profit and loss of operating segments are mainly measured by the operating profit, which also serves as the basis for performance evaluation. The reported amounts are consistent with the reporting to the operational decision makers. In addition to the aforementioned, the accounting policies of the operating segments do not differ significantly from the material policies of the Group.

The Group's operating segment information and reconciliation are as follows:

	January to March 2026			
	R&D and Manufacturing Division	**Medical Services Division**	**Adjustment and Elimination**	**Total**
External revenue	$ 215,439	1,109,168	-	1,324,607
Intra-group revenue	19,911	55	(19,966)	-
Total segment revenue	$ 235,350	1,109,223	(19,966)	1,324,607
Segment profit (loss)	$ (6,982)	76,231	223	69,472

	January to March 2025			
	R&D and Manufacturing Division	**Medical Services Division**	**Adjustment and Elimination**	**Total**
External revenue	$ 226,612	1,001,346	-	1,227,958
Intra-group revenue	16,737	32	(16,769)	-
Total segment revenue	**$ 243,349**	**1,001,378**	**(16,769)**	**1,227,958**
Segment profit (loss)	**$ 5,124**	**67,504**	**222**	**72,850**